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Abstract Acute pulmonary embolism (PE) is diagnosed ei-
ther by ventilation/perfusion (V/P) scintigraphy or pulmonary
CTangiography (CTPA). In recent years both techniques have
improved. Many nuclear medicine centres have adopted the
single photon emission CT (SPECT) technique as opposed to
the planar technique for diagnosing PE. SPECT has been
shown to have fewer indeterminate results and a higher diag-
nostic value. The latest improvement is the combination of a
low-dose CT scan with a V/P SPECT scan in a hybrid
tomograph. In a study comparing CTPA, planar scintigraphy
and SPECT alone, SPECT/CT had the best diagnostic accu-
racy for PE. In addition, recent developments in the CTPA
technique have made it possible to image the pulmonary
arteries of the lungs in one breath-hold. This development is
based on the change from a single-detector to multidetector
CT technology with an increase in volume coverage per
rotation and faster rotation. Furthermore, the dual energy CT
technique is a promising modality that can provide functional
imaging in combination with anatomical information. Newer
high-end CT scanners and SPECT systems are able to visual-
ize smaller subsegmental emboli. However, consensus is lack-
ing regarding the clinical impact and treatment. In the present
review, SPECTand SPECT in combination with low-dose CT,
CTPA and dual energy CT are discussed in the context of
diagnosing PE.
Keywords SPECT . SPECT/CT . Pulmonary CT
angiography . Lung scintigraphy . Pulmonary embolism .
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Introduction
Acute pulmonary embolism (PE) is a common, often undiag-
nosed and potentially fatal disease. Mortality is between 10 %
and 30 % if untreated, but can be reduced to 2 – 8 % with
treatment [1]. Various clinical symptoms and findings together
with knowledge of predisposing factors may strengthen or
weaken the clinical suspicion. PE can be ruled out if the
clinical suspicion is low and the D-dimer test is negative.
However, in those patients in whom the clinical suspicion is
moderate or high and/or the D-dimer test is positive, a con-
clusive imaging test such as a ventilation/perfusion (V/P)
study or pulmonary CT angiography (CTPA) is needed to
confirm or exclude the diagnosis of PE. There is increasing
evidence of the improved accuracy of single photon emission
CT (SPECT) and SPECT combined with low-dose CT
(SPECT/CT) compared to planar V/P scintigraphy, and like-
wise of multidetector CTPA compared to single-detector
CTPA. There is, however, less evidence concerning compar-
isons between SPECT and SPECT/CT and CTPA.
In this article, the clinical value and protocols of lung V/P
studies with SPECT, SPECT/CT and CTPA are discussed.
Imaging agents
Ventilation
For ventilation studies with SPECT several kinds of agents
can be used: the inert gas 81mKr, 99mTc-based agents such as
the carbon suspension Technegas, or radioaerosols, e.g.
99mTc-DTPA.
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81mKr is delivered from a 81Rb/81mKr generator. The short
half-life of 13 s implies that 81mKr is inhaled continuously
during imaging and that it disappears from the alveolar re-
gions by decay much faster than by expiration. Hence, at
normal breathing frequency the regional 81mKr concentration
reflects regional ventilation. Due to the higher gamma energy
(190.6 keV) of 81mKr compared to 99mTc (140 keV), a V/P
scan can be acquired simultaneously. The effective radiation
dose of 81mKr is very low (27 nSv/MBq, <0.2 mSv for 6,
000 MBq). The use of 81mKr is mainly limited by the distance
to a cyclotron since a cyclotron-produced generator only lasts
1 day (T½ of 4.6 h for
81Rb). 81mKr is very cost-effective if the
number of patient examinations is high in a centre, whereas
cost is a limitation if only a few patients are examined per
generator. 133Xe is rarely used in SPECT due to its low
availability and energy.
The 99mTc-labelled Technegas (Cyclomedica Australia,
Australia) consists of small 99mTc-graphite particles
(5 – 200 nm) that are generated by burning solid graphite
particles and 99mTc-pertechnetate in argon gas at a high tem-
perature. The particles grow by aggregation and should there-
fore be administered within 3 min (no more than 10 min). The
patient takes one to three deep breaths before imaging and
most particles are deposited by diffusion in the alveolar re-
gions, with a biological residence T½ of 135 h. As a result, the
time to start imaging, and the duration of image acquisition,
are not time-critical [1]. However, due to sedimentation, hot-
spots may occur in the larger airways and radioactivity may
travel up through the airways by mucociliary and cough
clearance during the SPECT. The effective radiation dose
(15 μSv/MBq, 0.5 – 0.8 mSv for 30 – 50 MBq) is higher than
for 81mKr and radioaerosols, but lower than for the perfusion
agent [1].
Radioaerosols are generated by a nebulizer, preferably
creating particles of 1 – 3 μm (mass median aerodynamic
diameter). If inhaled slowly they will deposit by sedimenta-
tion in the small airways and alveolar regions. The timing and
length of imaging examination may be important since reten-
tion in the lung depends on the type of ventilation agent used.
99mTc-DTPA will clear through the alveolar capillary mem-
brane (through tight-junctions) especially in the dependent
lung zones with a T½ of about 60 min in non-smokers, but
two to five times faster in current smokers. Rapid clearance is
reflected by the early depiction of radioactivity in the kidneys.
Correction for clearance of 99mTc-DTPA during the time span
of SPECT has been suggested and applied by some authors
[2]. However, correction is not necessary for 99mTc-colloids
(e.g. albumen, sulphur) since they have longer residence times
in the lungs. Hot-spots in the larger airways occur more often
with radioaerosols than with Technegas. The effective radia-
tion dose from radioaerosols is low: 7μSv/MBq, 0.21mSv for
30 MBq for 99mTc-DTPA; 4.7 μSv/MBq, 0.15 mSv for
30 MBq for 99mTc-albumin colloid (Venticoll) [1]. In centres
with only a few V/P studies, radioaerosols are the most cost-
effective ventilation agents.
Perfusion
99mTc-labelled macroaggregated human albumin (99mTc-
MAA) is injected slowly while the patient breathes slowly
and deeply to ensure a uniform perfusion distribution. The
administered dose is between 100 and 220 MBq (effective
dose 11 μSv/MBq, 1.1 – 2.4 mSv for 100 – 220 MBq) and
depends mainly on the choice of ventilation agent used [1, 3].
A larger dose is required if perfusion imaging is preceded by
99mTc-based ventilation imaging to overcome “background”
radiation from the ventilation agent. Indeed, some centres use
300 MBq99mTc-MAA [4] to obtain a required P/V ratio of ≥4
when using the ventilation agent Technegas, whereas a lower
99mTc-MAA dose can be used with 81mKr ventilation, or if the
perfusion study is not preceded by a ventilation study [1].
About 400,000 MAA particles are injected, except in patients
with pulmonary hypertension or a right-to-left cardiac shunt,
and in children, in whom fewer particles are used [5].
Scanning protocols
V/P SPECT
The ventilation and perfusion agents for SPECT should be
administered with the patient lying supine to reduce any
gravitational influence upon distribution. If a 99mTc-based
ventilation agent is used, sequential imaging is performed;
usually ventilation first, then perfusion. To ensure alignment
of the ventilation and perfusion imaging, the patient must not
move between the two acquisitions. If 81mKr is used, V/P
imaging can be performed simultaneously (applying a
photopeak of 190 keV for 81mKr and 140 keV for 99mTc-
MAA) ensuring optimal alignment and minimizing acquisi-
tion time; alternatively, 81mKr and 99mTc-MAA can be admin-
istered and imaged sequentially [1, 5].
Below are examples of different V/P SPECT scanning
protocols (Table 1):
& A sequential V/P SPECT protocol using 99mTc-DTPA
radioaerosol/99mTc-MAA [2]. First, the delivered dose
from 30 MBq 99mTc-DTPA is inhaled into the lungs, and
then the V SPECT is acquired. Immediately afterwards,
100 MBq 99mTc-MAA is given intravenously, and then
the P SPECT is acquired. Both SPECT datasets are ob-
tained with 64 projections per head over 180°, 10 s for
ventilation and 5 s for perfusion, using low-energy
general-purpose (LEGP) collimators and a 64 × 64matrix.
The protocol including both SPECT scans takes 20 min.
Ordered-subsets expectation maximization (OSEM)
S82 Eur J Nucl Med Mol Imaging (2014) 41 (Suppl 1):S81–S90
reconstruction is performed (two iterations/eight subsets).
Since 10 – 40 % of the 99mTc-DTPA is cleared from the
lungs during the V SPECT acquisition, this is corrected
for. In addition, P SPECT is corrected for “background”
radioactivity remaining from the 99mTc-ventilation agent.
& A sequential V/P SPECT protocol using 99mTc-
Technegas/99mTc-MAA [3]. First, a dose from 50 MBq
99mTc-Technegas is inhaled into the lungs, and then the V
SPECT is acquired. Immediately afterwards, 220 MBq
99mTc-MAA is given intravenously, and then the P SPECT
is acquired. Both SPECT datasets are obtained with 60
projections per head over 180°, 12 s for ventilation and 8 s
for perfusion, using low-energy high-resolution (LEHR)
collimators and a 128 × 128 matrix. The protocol includ-
ing both SPECT scans takes 25 – 30 min. OSEM recon-
struction is used (eight iterations/four subsets).
& A simultaneous V/P SPECT protocol using 81mKr/99mTc-
MAA [6]. First, 150 MBq 99mTc-MAA is given intrave-
nously, then the V/P SPECT scan is performed, during
which 81mKr is inhaled. Dual energy SPECT is acquired as
36 projections per head of 20 s each over 180°, using
LEGP (or medium-energy general-purpose) collimators
and a 128 × 128 matrix. The protocol takes 13 min.
Iterative reconstruction is performed (three iterations/16
subsets; Astonish, Philips) and images both with attenua-
tion correction (based on a simultaneously obtained low-
dose CT scan) and without attenuation correction are
reviewed. Our present routine protocol is shortened to less
than 10 min by using 12 s instead of 20 s per projection.
SPECT/CT
The introduction of hybrid SPECT/CT tomography has en-
abled simultaneous acquisition of V/P SPECTand CTscans of
the lungs [9]. CT can be performed as a low-dose CT scan of
the lungs and/or as CTPA [6, 9]. In our centre, the standard
routine test for evaluation of PE is combined 81mKr/99mTc-
MAA (V/P) SPECT/CT (16 slice Precedence; Philips); the CT
is performed as a low-dose CT scan without contrast enhance-
ment during free breathing (140 kVp, 20 mAs/slice, collima-
tor 16 × 1.5 mm, rotation time 0.5 s, pitch 0.813, matrix
512 × 512) immediately before the V/P SPECT scan. The
total time required for the combined study is <15 min. The
effective radiation dose from the low-dose CT scan is about
1 mSv [6]. A similar dose of 0.9 mSv from a CT scan
(110 kVp, 20 mAs/slice) has been reported from a V/P
SPECT/CT study from Perth, Australia [10].
In a prospective study comparing simultaneously per-
formed V/P SPECT, V/P SPECT/CT and CTPA [6], we in-
cluded CTPA (80 ml iodine contrast agent, 350 mgI/ml) using
the bolus tracking technique during a deep inspiration breath-
hold (120 kVp, 230 mAs/slice, collimator 16 × 0.75 mm,
rotation time 0.5 s, pitch 0.94, 512 × 512 matrix). In our dailyTa
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routine, we occasionally combine V/P SPECT/CT and CTPA
in critically ill patients, and in such cases, we start with CTPA.
If negative for central PE, we proceed with V/P SPECT/CT to
detect any peripheral PE. The combined V/P SPECT/CT and
CTPA can be performed in <20 min.
Pulmonary multidetector CT angiography
Over the past two decades, CT has undergone rapid develop-
ment. From single-detector CT to an increasing number of
rows of detectors (multidetector CT, MDCT), with an increase
in volume coverage in one rotation time and a decrease in the
time necessary to acquire the entire chest, all of which have
made it possible to image the pulmonary arteries of the lungs
in one breath-hold [11]. In the latest generation of CT systems
several benefits have been achieved, such as: significant de-
crease in the volume of iodine contrast agent injected, faster
scan time (<1 s) and lower radiation dose. With the introduc-
tion of iterative reconstruction algorithms and faster scan
times, it is now possible to lower the peak kilovoltage from
120 to 80 kVp and, with the use of dose modulation software,
to decrease the radiation dose in selected systems by >70 %
without compromising the signal-to-noise ratio [12]. An ef-
fective dose for CTPA of ≤1 mSv is now achievable with the
state-of-the-art systems available [13].
The development of faster scan times has further resulted in
a decreased number of inconclusive scans from approximately
10% to 2 %. These are most often due to patient movement or
poor bolus enhancement [14–16]. Additionally, continuous
improvement of the contrast agent injection protocols has to
be achieved due to the shorter scan times. The paramount
challenge is in timing the intravenous injection of the contrast
agent bolus and accomplishing high contrast enhancement in
the pulmonary vessels and at the same time lowering the
volume of contrast agent administered to reduce the adverse
effects of iodine (Fig. 1). Consequently, the volume of iodine
contrast agent required can be reduced to 60 – 70 ml
(300 – 400 mg I/ml) with the fast high-end systems compared
to 150 ml with older systems (2 – 16 detectors). Nonetheless,
impairment of kidney function is still an important issue with
iodine contrast agents.
The latest improvement in CT is the development of dual
energy CT systems. A dual energy CT system with two
independent tube detector systems (e.g. 140 kVp and
80 kVp) makes material differentiation possible. Iodine distri-
bution can be visualized in the parenchyma of the lung and
can reveal perfusion changes and has the potential to reveal
subsegmental clots. In addition, stable xenon gas can be used
in dual energy CT systems for CT ventilation imaging, mim-
icking the ventilation scan obtained in lung scintigraphy [17].
Hence, it is now feasible to accomplish functional information
(perfusion/ventilation) combined with morphological imaging
in the same lung CT scan [18, 19]. However, further studies
have to be done before this can be applied in routine clinical
practice.
Clinical value
V/P SPECT
V/P SPECTovercomes the superimposition of lung areas with
normal perfusion onto areas with perfusion defects, which
may mask PE. It also allows recognition of perfusion and
ventilation defects typical of other diseases. Many studies
demonstrate enhanced sensitivity and specificity, as well as a
reduction in the nondiagnostic rate of V/P SPECT compared
with planar V/P scintigraphy [4, 20–23] (Table 2). In clinical
head-to-head comparisons of V/P SPECT and planar scintig-
raphy, more and smaller defects were seen on SPECT and
higher sensitivity, specificity and accuracywere also observed:
the median differences between SPECT and planar V/P scans
in sensitivity, specificity and accuracy were 21 % (range 15 to
36 %), 6 % (range −7 to 15 %) and 7 % (range −2 to 20 %),
respectively [20–22]. A substantial proportion of V/P planar
studies are usually indeterminate (up to 73 % in PIOPED1),
but the addition of V/P SPECT renders the test diagnostic in
most patients [4]. V/P SPECT is diagnostic in ≥95 % of
Fig. 1 Bilateral central
pulmonary emboli on the CT
scan. Axial and coronal CT
images with intravenous contrast
agent administration show large
contrast defects in the central
pulmonary arteries (arrows).
Note the lack of contrast
enhancement in the small
subsegmental pulmonary arteries
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patients and is feasible in 97 – 99 % of patients referred for
lung scintigraphy [6, 24–26]. V/P planar scintigraphy remains
an alternative in the few patients in whom SPECT cannot be
performed due to for example obesity or discomfort in the
supine position [24].
Some patterns on V/P SPECT may suggest alternative
diagnoses such as COPD, pneumonia, and left heart diseases
[24, 27, 28] but even if these diseases are present it is possible
to diagnose PE with V/P SPECT [1]. A recent study showed
that if the reader has extensive experience with PISA-PED
readings of perfusion scintigraphy, it is also possible to obtain
high diagnostic accuracy (≥90 %) for PE from perfusion
SPECT only without ventilation information [29].
Interpretation criteria of V/P SPECT
Iterative reconstruction is recommended (for example using
OSEM, with e.g. eight subsets and two iterations) [1]. Perfu-
sion and ventilation images in axial, coronal and sagittal
projections and rotating 3-D images are read simultaneously.
As an option, V/P ratio images can also be displayed [1] as
well as low-dose CT images, if available [6] (Fig. 2).
Different diagnostic cut-off criteria have been used in the
published V/P SPECT studies. Le Duc-Pennec et al. applied
the revised PIOPED criteria as proposed by Gottschalk et al.
for planar V/P scan interpretation [7, 30]. In a reanalysis of
249 V/P SPECT datasets assessing various combinations of
mismatched defect numbers and sizes from segmental to
subsegmental, the same authors found that a diagnostic cut-
off of one segmental or two subsegmental mismatches was
best for confirming or excluding acute PE with a sensitivity of
92 % and specificity of 91 % [31]. Combining pretest clinical
probability with SPECT for a negative V/P SPECT result gave
post-test probabilities of PE of 1 %, 4 % and 12 % for low,
intermediate and high clinical probability, respectively. For a
positive V/P SPECT result, post-test probabilities of PE were
53 %, 81 % and 94 % for low, intermediate and high clinical
probability, respectively (Table 2).
Leblanc et al. applied the diagnostic criteria for PE of “any
clear-cut vascular mismatch, regardless of size”, which had a
negative predictive value of 98 % at 3 months [26]. An almost
similar diagnostic cut-off of wedge-shaped pleural-based V/P
mismatch of ≥0.5 segment has been used by others [6, 8] and has
recently been shown to be the best value in a V/P planar study
[32]. A third approach was a cut-off of the presence of >50 %
perfusion mismatch in an anatomical segment or two regions of
perfusion mismatch, regardless of size [10].
The European (EANM) guidelines from 2009 recommend
that “PE” is reported if there is V/P mismatch of one or more
segments or two subsegments that conform to the pulmonary
vascular anatomy. “No PE” is reported if there is a normal
perfusion pattern conforming to the anatomic boundaries of
the lung, matched or reversed mismatch V/P defects (any size,
shape, number), or a mismatch that does not have a
subsegmental, segmental or lobar pattern. “Non-diagnostic
for PE” is reported if there are multiple V/P abnormalities
not typical of specific disease [1].
Clinical validity of PE-negative V/P SPECT studies
and clinical outcome
The negative predictive value of V/P SPECT for PE is ≥97 %
[6, 24–26]. The long-term outcome of withholding antithrom-
botic treatment after a negative SPECT scan has been studied
[25, 26] in 1,159 and 405 patients and only 0.5 – 1.5 % of the
scans were false-negative [24, 26], similar to reported values
for V/P planar studies [33–35].
Follow-up with V/P SPECT
In the same manner as the use of V/P planar lung scintigraphy
for follow-up after large PE, SPECT should be ideal for
follow-up studies due to its higher resolution and accuracy.
A prospective study of 23 patients with PE showed the feasi-
bility of follow-up with V/P SPECT for evaluating treatment
effectiveness and identifying patients who develop chronic
PE. Resolution of perfusion defects after PE occurred within
the first 3 months of treatment [36].
V/P SPECT/CT
The accuracy of V/P SPECT combined with low-dose CT has
been assessed in two studies (Table 2). In a prospective study,
simultaneously obtained V/P SPECT, V/P SPECT/CT and
CTPA were compared and PE was diagnosed in 38 % using
head-to-head comparisons and 6 months follow-up [6]. V/P
SPECT and V/P SPECT/CT had the highest sensitivity
(97 %), whereas V/P SPECT/CT and CTPA had the highest
specificity (100 %), and V/P SPECT/CT had the highest
accuracy (99 %). Differences were not significantly different,
however, due to the relatively small number of patients. A test
that included V/P SPECT gave the highest sensitivity, while a
test that included CT, either CTPA or low-dose CT integrated
with V/P SPECT, gave the best specificity and was always
either positive or negative for PE (100 % diagnostic rate) and
could often give alternative diagnoses. Adding low-dose CT
to V/P SPECT increased specificity (from 88 % to 100 %) by
reducing false-positive interpretations (from 18 % to 0 %),
without affecting sensitivity (still 97 %). Low-dose CT im-
proved confidence in reading and reduced the inconclusive
assessments from 5 % to 0 %. The improvement in specificity
was mainly due to low-dose CT findings providing alternative
explanations for subtle perfusion defects such as small
interlobar fissures, localized hyperinflated areas, paraseptal
emphysema, pleural fluid, atelectasis and pneumonic infiltra-
tion, which would otherwise be read as PE on SPECT (Fig. 3).
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However, low-dose CT combined with perfusion SPECT
(without ventilation SPECT) was suboptimal due to a low
specificity (51 %) and positive predictive value (57 %) and a
high nondiagnostic rate (17 %), while sensitivity and negative
predictive value remained over 90 %. Hence, ventilation
SPECT is needed in addition to perfusion SPECTwhen using
low-dose CT.
Ling et al. performed V/P SPECT/CT in 106 patients using
a composite reference standard for PE including a 6-month
follow-up, but CTPA was only used in a few patients with
normal V/P scans but high clinical suspicion [10]. PE was
diagnosed in 26 % of patients, including 2 % with a false-
negative V/P SPECT/CT result. The negative predictive value
of V/P SPECT for PE was 97 %. Abnormalities detected by
low-dose CTwere correlated with the V/P SPECT findings to
suggest alternative diagnoses in those negative for PE. Low-
dose CTwas abnormal in 41 % of patients, and in 27 % of all
patients low-dose CT provided information on alternative
Fig. 2 A pulmonary embolus is
seen on the V/P SPECT/CT
images. Awedge-shaped pleural-
based large mismatched perfusion
defect is seen anteriorly in the left
lung (yellow arrows) on the axial
(upper row), coronal (middle
row) and sagittal (lower row)
projections. No other
explanations for the perfusion
defect can be seen on the normal
ventilation scan and low-dose CT
images
Fig. 3 Very small mismatched
perfusion defects (yellow arrows)
are seen peripherally in both
lungs, but the CT image shows
widespread pleural based
interstitial ground-glass
abnormalities (blue arrows)
compatible with inflammation,
but not with PE
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pathologies that accounted for the symptoms such as pneu-
monia, pulmonary oedema and ARDS, corresponding to the
CTPA findings [37]. Performing low-dose CT allows attenu-
ation correction of the SPECT data. The value of attenuation
correction of V/P SPECT studies in PE is, however, unre-
solved [3].
Another potential combination of functional and structural
information from V/P SPECT and CT is a fusion of SPECT
and CTPA scan acquired on the same or separate systems [9,
38]. Accurate fusion of SPECT and CTPA may be clinically
useful in nondiagnostic initial investigations, or where corrob-
orative imaging is sought.
Pulmonary CT angiography
Several studies have demonstrated that CTPA has higher
diagnostic accuracy and specificity than planar V/P scintigra-
phy [19, 37]. In a study with 179 patients, Blachere et al.
demonstrated that sensitivity, specificity, positive predictive
value and negative predictive value of CTPA and planar V/P
scans were 94 % versus 80%, 93 % versus 73%, 95% versus
82 % and 96 % versus 75 %, respectively [19]. Similar results
were reported by Grenier and Beigelman [39] and Mayo et al.
[40]. The strength of V/P scintigraphy is its high negative
predictive value in patients with a low pretest probability and
its high positive predictive value in patients with a high pretest
probability [30]. Hence, it was part of the composite gold
standard for diagnosing PE in the PIOPED2 study, in which
CTPA had a sensitivity of 83 % and specificity of 96 % and
was inconclusive in 6 % [14].
The number of head-to-head comparisons between V/P
SPECT and CTPA is still limited (Table 2) [6, 8, 22]. There
is a 95 % concordance between V/P SPECT and CTPA [8],
with a higher sensitivity with SPECT, a higher specificity with
CTPA, and equally high accuracy with both methods [6, 22].
The combination of V/P SPECT and low-dose CT may be
even more accurate than V/P SPECT or CTPA, but more
studies are warranted [6].
V/P SPECT and V/P SPECT/CT are available in many
nuclear medicine departments, mostly during routine working
hours. They can provide alternative diagnoses, have high
interobserver agreement, and can be performed in almost all
patients since there are no definitive contraindications [1, 41].
CTPA is available in most clinical centres round-the-clock. It
is capable of providing alternative diagnoses, has faster scan
times, has high interobserver agreement and could have a
possible role in detecting right ventricular dysfunction. It does
have contraindications, however, and cannot be performed in
10 – 30 % of inpatients [6, 11, 14, 42].
Patients with PE may have multiple scans due to the risk of
recurrence or due to comorbidity, and therefore are at risk
from cumulative exposure to ionizing radiation. Especially in
young women, the radiation dose to the breast tissue is of
critical importance. Chest CT scanning results in relatively
higher doses to the breast tissue than lung scintigraphy. How-
ever, the latest iterative reconstruction technique can lead to a
60 – 80% reduction in dose, and at the same time, a 43 – 80%
improvement in low-contrast detectability and a 70 – 83 %
reduction in image noise, compared with standard (filtered
back projection) reconstruction. Therefore, radiation dose to
the breast can be reduced [13, 43]. However, there is no broad
consensus on this issue and further research is needed.
Clinical validity of PE-negative CT studies and clinical
outcome
Carrier et al. demonstrated in a systematic review that multiple
detector CTPA (2 – 64 detectors) might increase the rate of
subsegmental PE diagnosis as compared with single detector
CTPA. They also demonstrated that the 3-month thromboem-
bolic risk in patients with suspected PE who were left untreat-
ed after a negative CTPA result was similar regardless of
whether the patients underwent a single or multiple detector
CTPA. Finally, they concluded that the incremental rate of
subsegmental PE detected by multiple detector CTPA might
not be clinically important [44].
A meta-analysis by Quiroz et al. with pooled results in-
volving 15 studies and 3,500 patients with suspected PE
suggested that clinical outcome is not adversely affected if
anticoagulant therapy is withheld based on a negative CTscan
with a negative predictive value of 99.1 % [45]. These studies
were performed with older generation MDCT systems, and it
is therefore possible that subsegmental pulmonary emboli
remained undetected. Newer high-end CT systems have a
higher spatial and temporal resolution and are therefore able
to visualize smaller subsegmental emboli. However, consen-
sus regarding the treatment of isolated subsegmental emboli in
patients with suspected PE has not been established and
whether this will result in improved clinical outcome is de-
batable [46]. Since subsegmental PE may precede recurrent
large PE and may also increase the risk of development of
chronic pulmonary hypertension, improvement in the detec-
tion of subsegmental PE is worth studying [18].
Conclusion
Compared with traditional V/P scintigraphy, both V/P SPECT
and CTPA have a higher diagnostic value and fewer incon-
clusive results in the diagnosis of PE. V/P SPECT and CTPA
are highly concordant and show similar diagnostic accuracy,
with SPECT showing higher sensitivity and CTPA higher
specificity. There is possibly a higher clinical value of nega-
tive SPECT studies compared to negative CTPA studies, but
the clinical importance of finding a small subsegmental PE
needs further elucidation. A combination of V/P SPECT and
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CT may be even more accurate than V/P SPECT or CTPA
alone. More comparisons are needed, however. Each of these
excellent imaging methods has the highest predictive values
when there is concordance between the clinical suspicion and
the test result, whereas further imaging should be performed if
there is discordance.
V/P SPECT or V/P SPECT/CT are available in many
nuclear medicine departments, mostly during the day-time.
They may provide an alternative diagnosis if PE is refuted,
and are feasible in almost all patients, because there are no
definitive contraindications. CTPA is usually available round-
the-clock and a rapid PE or alternative diagnosis can be
expected. Due to contraindications such as kidney impairment
or allergy, CTPA cannot be performed in about 10 – 30 % of
patients. Whereas radiation exposure was previously substan-
tially higher for the patient with CTPA than with V/P SPECT
or V/P SPECT/CT, a much lower radiation dose is now
achievable with new generation CT technology.
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